Abstract
2568Background: Evofosfamide (Evo) is a prodrug of Br-IPM that is preferentially activated under hypoxic conditions. Hypoxia in locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have